Avalo Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Avalo Therapeutics
AVTX Stock  USD 7.77  0.08  1.04%   
Avalo Therapeutics financial statements provide useful quarterly and yearly information to potential Avalo Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Avalo Therapeutics financial statements helps investors assess Avalo Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Avalo Therapeutics' valuation are summarized below:
Gross Profit
-9.3 M
Market Capitalization
80.7 M
Enterprise Value Revenue
2.7414
Revenue
820 K
Earnings Share
94.42
We have found one hundred twenty available fundamental signals for Avalo Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Avalo Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 2.2 M in 2025. Enterprise Value is likely to rise to about (3.7 M) in 2025

Avalo Therapeutics Total Revenue

1.65 Million

Check Avalo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Avalo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 172.6 K, Interest Expense of 5.6 M or Selling General Administrative of 11.9 M, as well as many indicators such as Price To Sales Ratio of 1.44, Dividend Yield of 0.0 or PTB Ratio of 0.38. Avalo financial statements analysis is a perfect complement when working with Avalo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Avalo Therapeutics Correlation against competitors.
For more information on how to buy Avalo Stock please use our How to Invest in Avalo Therapeutics guide.

Avalo Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets37.3 M24.1 M28.1 M
Slightly volatile
Other Current Liabilities4 M4.2 M6.3 M
Slightly volatile
Total Current Liabilities5 M5.3 M9.3 M
Slightly volatile
Property Plant And Equipment Net2.4 M2.3 M985.6 K
Slightly volatile
Accounts Payable487.3 K512.9 K1.5 M
Very volatile
Cash15.2 M8.5 M11.6 M
Slightly volatile
Non Current Assets Total16.6 M14.5 M12.5 M
Slightly volatile
Non Currrent Assets Other112 K117.9 K370.1 K
Slightly volatile
Cash And Short Term Investments16 M8.5 M12.2 M
Slightly volatile
Common Stock Shares Outstanding335.4 K319.4 K83.8 K
Slightly volatile
Liabilities And Stockholders Equity37.3 M24.1 M28.1 M
Slightly volatile
Non Current Liabilities Total12.1 M8.2 M15.3 M
Pretty Stable
Other Current Assets1.4 M970.6 K1.2 M
Slightly volatile
Other Stockholder Equity413.5 M393.8 M153.6 M
Slightly volatile
Total Liabilities29 M15.7 M25.2 M
Pretty Stable
Total Current Assets9.2 M9.7 M14.9 M
Slightly volatile
Common Stock855900187 K
Very volatile
Short and Long Term Debt Total586.7 K617.5 K8.2 M
Very volatile
Short Term Debt459.1 K483.3 K1.6 M
Pretty Stable
Net Receivables116.3 K122.4 K1.7 M
Pretty Stable
Other Liabilities5.8 M6.3 M5.6 M
Pretty Stable
Other Assets0.860.92 M
Very volatile
Good Will11.3 M9.5 M13.7 M
Slightly volatile
Common Stock Total Equity64.1 K67.5 K1.4 M
Slightly volatile
Net Invested Capital6.2 M6.6 M24.3 M
Slightly volatile
Property Plant And Equipment Gross1.9 M2.9 M1.1 M
Slightly volatile
Non Current Liabilities Other3.3 M3 M3.9 M
Pretty Stable
Intangible Assets32.5 K34.2 K11 M
Slightly volatile
Property Plant Equipment1.6 M2.8 M993.7 K
Slightly volatile
Long Term Debt16.2 M12.1 M17.7 M
Pretty Stable
Short and Long Term Debt3.8 M6.8 M3.1 M
Slightly volatile
Capital Stock85590040.1 K
Slightly volatile
Capital Surpluse161.8 M182 M198.5 M
Slightly volatile
Capital Lease Obligations544.6 K617.5 K462.9 K
Slightly volatile
Deferred Long Term Liabilities72.3 K81.4 K88.7 K
Slightly volatile
Preferred Stock Total Equity1 K1.1 K1.2 K
Slightly volatile

Avalo Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization172.6 K181.7 K584.5 K
Pretty Stable
Interest Expense5.6 M3.9 M4.1 M
Slightly volatile
Selling General Administrative11.9 M11.8 M9.7 M
Slightly volatile
Other Operating Expenses35.6 M29.2 M28.7 M
Slightly volatile
Research Development19.7 M15.9 M16.2 M
Slightly volatile
Total Operating Expenses699.2 K736 K22.4 M
Pretty Stable
Total Revenue1.6 M1.7 M6 M
Pretty Stable
Selling And Marketing Expenses28.2 K29.7 K1.4 M
Very volatile
Cost Of Revenue1.1 M1.2 M2.1 M
Pretty Stable
Reconciled Depreciation128.2 K135 K995.1 K
Very volatile
Interest Income68.1 K44 K95.1 K
Slightly volatile
Non Recurring20.4 M23 M25.1 M
Slightly volatile
Non Operating Income Net Other4.5 M5.1 M5.5 M
Slightly volatile

Avalo Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.4 M4 M2.8 M
Slightly volatile
Begin Period Cash Flow14.3 M15.3 M11.8 M
Slightly volatile
Depreciation172.6 K181.7 K824.2 K
Pretty Stable
Capital Expenditures127.8 K181.7 K108.1 K
Slightly volatile
End Period Cash Flow14.9 M8.7 M12.8 M
Pretty Stable
Dividends Paid13.4 M17 M8.1 M
Slightly volatile
Issuance Of Capital Stock32.9 M53.2 M18.5 M
Slightly volatile
Cash And Cash Equivalents Changes12.3 M13.8 M15.1 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.441.512.2 K
Slightly volatile
Days Sales Outstanding22.0623.2263.7537
Pretty Stable
Average Payables1 M1.6 M1.4 M
Slightly volatile
Stock Based Compensation To Revenue1.692.082.2669
Slightly volatile
Capex To Depreciation0.610.660.5958
Slightly volatile
Inventory Turnover12415579.6205
Slightly volatile
Days Of Inventory On Hand2.322.4418.7305
Very volatile
Payables Turnover4.463.315.2014
Slightly volatile
Sales General And Administrative To Revenue5.746.147.9977
Slightly volatile
Average Inventory377.2 K671.8 K443.8 K
Slightly volatile
Research And Ddevelopement To Revenue7.838.2424.0974
Slightly volatile
Capex To Revenue0.09920.09440.0596
Slightly volatile
Cash Per Share29.1730.75.6 K
Slightly volatile
Days Payables Outstanding1391461 K
Very volatile
Income Quality0.911.120.8627
Very volatile
Intangibles To Total Assets0.530.580.6038
Slightly volatile
Current Ratio2.382.092.7021
Slightly volatile
Receivables Turnover10.7316.279.4076
Pretty Stable
Capex Per Share0.620.6510.193
Pretty Stable
Average Receivables449.2 K472.8 K978.7 K
Slightly volatile
Revenue Per Share7.577.97538
Very volatile
Interest Debt Per Share15.5516.373.4 K
Slightly volatile
Debt To Assets0.02790.02940.3219
Slightly volatile
Graham Number10.8 K12.1 K13.2 K
Slightly volatile
Operating Cycle28.1929.6775.4266
Pretty Stable
Days Of Payables Outstanding1391461 K
Very volatile
Ebt Per Ebit0.921.211.1229
Pretty Stable
Quick Ratio2.372.092.6963
Slightly volatile
Net Income Per E B T0.780.90.9073
Slightly volatile
Cash Ratio1.981.852.357
Slightly volatile
Days Of Inventory Outstanding2.322.4418.7305
Very volatile
Days Of Sales Outstanding22.0623.2263.7537
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.90.996
Slightly volatile
Fixed Asset Turnover1.071.1349.2389
Very volatile
Debt Ratio0.02790.02940.3219
Slightly volatile
Price Sales Ratio1.441.512.2 K
Slightly volatile
Asset Turnover0.07840.08250.1832
Pretty Stable

Avalo Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 M2.3 M51.7 M
Pretty Stable

Avalo Fundamental Market Drivers

Cash And Short Term Investments7.4 M

Avalo Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
3rd of April 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Avalo Therapeutics Financial Statements

Avalo Therapeutics investors use historical fundamental indicators, such as Avalo Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Avalo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue101.2 K96.1 K
Total Revenue1.7 M1.6 M
Cost Of Revenue1.2 M1.1 M
Stock Based Compensation To Revenue 2.08  1.69 
Sales General And Administrative To Revenue 6.14  5.74 
Research And Ddevelopement To Revenue 8.24  7.83 
Capex To Revenue 0.09  0.10 
Revenue Per Share 7.97  7.57 
Ebit Per Revenue(10.97)(11.51)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Avalo Stock Analysis

When running Avalo Therapeutics' price analysis, check to measure Avalo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avalo Therapeutics is operating at the current time. Most of Avalo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avalo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avalo Therapeutics' price. Additionally, you may evaluate how the addition of Avalo Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY